SCHEMBL2006016

SCHEMBL2006016

[c]1cnnc2[nH]ccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2000256 0.65
SCHEMBL12612922 0.65 PRKCI (0.40)
SCHEMBL1828693 0.61
SCHEMBL1504325 0.60 PRKCI (0.52)
SCHEMBL1504285 0.60 PRKCI (0.52)
SCHEMBL329804 0.59
SCHEMBL574970 0.56
SCHEMBL1504315 0.55 PRKCI (0.35)
SCHEMBL1504418 0.55 DYRK1A (0.39)
SCHEMBL1565530 0.54 PRKCI (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3868758-B1 THIADIAZOLE DERIVATIVES AND USE THEREOF AS A GLS1 INHIBITORS FOR THE TREATMENT OF CANCER MEDSHINE DISCOVERY INC (CN) 2023-01-04 EP claimed
CN-112888686-B Thiadiazole derivatives and their use as GLS1 inhibitors 南京明德新药研发有限公司 2022-04-19 CN claimed
CN-112888686-A Thiadiazole derivatives and their use as GLS1 inhibitors 南京明德新药研发有限公司 2021-06-01 CN claimed
US-7897759-B2 Metabolically stable puromycin analogs MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-03-01 US claimed
EP-2038265-A2 HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE The Procter and Gamble Company (US) 2009-03-25 EP claimed
US-20090069556-A1 METABOLICALLY STABLE PUROMYCIN ANALOGS MEDICAL UNIVERSITY OF SOUTH CAROLINA 2009-03-12 US claimed
WO-2008002570-A2 HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THE PROCTER & GAMBLE COMPANY (US) 2008-01-03 WO claimed
US-20080004267-A1 Human protein tyrosine phosphatase inhibitors and methods of use THE PROCTER & GAMBLE COMPANY (US) 2008-01-03 US claimed
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
EP-4222142-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RaQualia Pharma Inc. (JP) 2023-08-09 EP disclosed
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2023-05-11 US disclosed
EP-4142874-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RaQualia Pharma Inc. (JP) 2023-03-08 EP disclosed
EP-3868758-B1 THIADIAZOLE DERIVATIVES AND USE THEREOF AS A GLS1 INHIBITORS FOR THE TREATMENT OF CANCER MEDSHINE DISCOVERY INC (CN) 2023-01-04 EP disclosed
US-20090069556-A1 METABOLICALLY STABLE PUROMYCIN ANALOGS MEDICAL UNIVERSITY OF SOUTH CAROLINA 2009-03-12 US disclosed
WO-2008103866-A1 SYNTHESIS OF INDOLES MICROBIA, INC. (US) 2008-08-28 WO disclosed
EP-1931632-A2 USEFUL INDOLE COMPOUNDS Microbia Inc. (US) 2008-06-18 EP disclosed
WO-2008019357-A2 INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. (US) 2008-02-14 WO disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
WO-2007022501-A2 USEFUL INDOLE COMPOUNDS MICROBIA, INC. (US) 2007-02-22 WO disclosed